Showing results (121-130 of 181) with videos related to

Sort By:
Pageof 19
Evolution; International Journal of Organic Evolution|January 27, 2026
Replicate avian hybrid zones reveal the progression of genetic and trait introgression through timeMaría Isabel Castaño, Elizabeth Croyle, Carlos Daniel Cadena, et al.
Diabetes Care|January 20, 2021
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension StudyLawrence Blonde, Julio Rosenstock, Juan Frias, et al.
Diabetes Care|March 18, 2009
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)Bernard Zinman, John Gerich, John B Buse, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 11, 2021
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence ResultsCristian Guja, Francesco Giorgino, Lawrence Blonde, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 18, 2014
Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetesJared A Dendy, Vijayaratna Chockalingam, Naga N Tirumalasetty, et al.
Diabetes, Obesity & Metabolism|December 23, 2017
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulinFang Liz Zhou, Fen Ye, Paulos Berhanu, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 9, 2020
Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort StudyXuejun Victor Peng, Rory J McCrimmon, Leah Shepherd, et al.
Diabetes, Obesity & Metabolism|June 26, 2018
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studySean D Sullivan, Timothy S Bailey, Ronan Roussel, et al.
Diabetes Care|September 19, 2019
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical TrialLawrence Blonde, Julio Rosenstock, Stefano Del Prato, et al.
Advances in Therapy|July 31, 2019
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L TrialLawrence Blonde, Timothy S Bailey, Jason Chao, et al.
Pageof 19